Midostaurin approved for FLT3-mutated AML

Research output: Contribution to journalArticlepeer-review

114 Scopus citations


Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.

Original languageEnglish (US)
Pages (from-to)3403-3406
Number of pages4
Issue number26
StatePublished - Jun 29 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Midostaurin approved for FLT3-mutated AML'. Together they form a unique fingerprint.

Cite this